AI assistant
Sending…
OptimizeRx Corp — Director's Dealing 2025
Dec 22, 2025
33090_dirs_2025-12-22_16ad99c4-1f29-4519-bf58-d0384dcbaf36.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2025-12-19
Reporting Person: Stelmakh Edward (Chief Finance & Strat Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | Common Stock | M | 5237 | — | Acquired | 128218 | Direct |
| 2025-12-19 | Common Stock | S | 1388 | $13.51 | Disposed | 126830 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-12-19 | Restricted Stock Units | $ | M | 5237 | Disposed | 2026-12-19 | Common Stock (5237) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.
F3: The restricted stock units vest in three equal annual installments beginning December 19, 2024, the first anniversary of the grant date.
More from OptimizeRx Corp
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 12
Board/Management Information
2026
Jun 5
Proxy Solicitation & Information Statement
2026
Jun 1
Regulatory Filings
2026
May 12
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Director's Dealing
2026
Feb 13
Director's Dealing
2025
Dec 23
Director's Dealing
2025
Dec 23
Director's Dealing
2025
Dec 23